Pilot Study of Human Tear Proteins

This study has been terminated.

(Stopped due to low enrollment)

Sponsor:

Information provided by (Responsible Party):

University of Colorado, Denver

ClinicalTrials.gov Identifier:

NCT00453258

First received: March 26, 2007

Last updated: January 15, 2013

Last verified: October 2012

History of Changes

Purpose

The significance of our study is in the importance of understanding the quality and quantity of proteins in the human tear film from diseased and non-diseased patients. This pilot study will provide data to plan prospective research to better delineate the utility of tear proteins in diagnosing and following disease status in a non-invasive fashion.

Condition	Intervention
Eye Disease	Other: Eye Examination


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Analysis of Human Tear Proteins: A Pilot Study to Describe the Tear Film Proteome of Patients Undergoing Ophthalmic Examination.

Resource links provided by NLM:

MedlinePlus related topics: Eye Diseases Health Checkup Tears

U.S. FDA Resources

Further study details as provided by University of Colorado, Denver:

Primary Outcome Measures:

Plan Prospective Research [ Time Frame: Throughout study participation ] [ Designated as safety issue: No ]
Pilot study will provide data to plan prospective research to better delineate the utility of tear proteins in diagnosing and following disease status in a non-invasive fashion.


Enrollment:	63
Study Start Date:	February 2007
Study Completion Date:	September 2011
Primary Completion Date:	September 2011 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
Study Subject Subjects receiving eye examination	Other: Eye Examination Subjects receiving eye examination

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Subjects receiving eye examination

Criteria

Inclusion Criteria:

18 years of age and older
able to cooperate with tear sample collection
provide written informed consent

Exclusion Criteria:

special populations (children, pregnant or lactating females, prisoners, etc)
refusal to sign sudy consent

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00453258

Locations


United States, Colorado
Rocky Mountain Lions Eye Institute
Aurora, Colorado, United States, 80045

Sponsors and Collaborators

University of Colorado, Denver

Investigators


Principal Investigator:	Malik Y. Kahook, MD	Rocky Mountain Lions Eye Institute

More Information


Responsible Party:	University of Colorado, Denver
ClinicalTrials.gov Identifier:	NCT00453258 History of Changes
Other Study ID Numbers:	06-0862
Study First Received:	March 26, 2007
Last Updated:	January 15, 2013
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Colorado, Denver:


ocular proteomics eye disease proteomics

Additional relevant MeSH terms:


Eye Diseases

ClinicalTrials.gov processed this record on September 26, 2016

To Top